The Extraordinary General Meeting of BioGaia AB (publ) on 18 March 2016 resolved
on:
· the approval of BioGaia’s transfers of 2,250 shares in BioGaia’s subsidiary
Infant Bacterial Therapeutics AB (“IBT”) to each of Eamonn Connolly and Staffan
Strömberg; and
· the distribution of all BioGaia’s shares, namely 74,066 shares of series A
and 1,659,579 shares of series B, in IBT, to BioGaia’s shareholders whereby one
(1) series A share in BioGaia shall entitle to one (1) series A share fraction
in IBT and one (1) series B share in BioGaia shall entitle to one (1) series B
share fraction in IBT. Ten series A share fractions shall entitle to one (1)
share of series A in IBT and ten series B share fractions shall entitle to one
(1) share of series B in IBT. In the event that a shareholder's holding in
BioGaia is not evenly divisible by ten, any excess share fractions that have not
entitled to shares in IBT will be sold, free of brokerage fees, on the
respective shareholder's behalf.
Latest press releases from BioGaia
2016-03-12 Meta-analysis confirms effectiveness of BioGaia ProDentis in
periodontitis
2016-03-12 Notice to attend the Extraordinary General Meeting of BioGaia AB
(publ)
2016-02-12 Proposal for distribution and separate listing of BioGaia’s
subsidiary Infant Bacterial Therapeutics
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 18 March 2016, 4.00
p.m. CET.
For additional information please contact
Peter Rothschild, Group President, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
